• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Consumer Cyclical·AAYUSH.BO
Share

Aayush Food and Herbs Limited Stocks

₹ 23.72Last Updated 23.07.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

₹ 12.27M

₹ 23.72
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Based in Mumbai, India, Aayush Wellness Limited, established in 1984, is dedicated to the development, manufacturing, marketing, and distribution of a variety of health and well-being products across India. Its extensive product range encompasses nutraceuticals, dietary supplements, herbal care items, beauty and personal wellness solutions, and preventive healthcare goods. Among its key offerings, sold under the Aayush brand, are a herbal pan masala for oral refreshment, "Dreamy Sleep Gummies" designed to promote better rest and relaxation, and "Beauty Vitamin Gummies" aimed at enhancing skin, hair, and nail health. The company, previously known as Aayush Food and Herbs Limited, officially adopted its current name, Aayush Wellness Limited, in July 2024.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. Specifically, the stock is 'expensive' on P/E, overvalued

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

25.07.2026 00:15

The YOLO strategy has backfired: traders' favorites are on track for their worst month in four years

24.07.2026 23:35

HSBC does not expect SpaceX's stock to rise. To value the stock, it had to abandon conventional methods.

24.07.2026 23:10

Freedom recommended buying Alphabet stock after the pullback. What could hinder its growth?

24.07.2026 22:45

Key Developments in the Kazakh Market: The Stakes of the Oil War and Signals from the National Bank

24.07.2026 22:34

"The Divorce of the Century": SK CEO to Pay Ex-Wife $643 Million but Retain Control of SK Hynix

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026